Fund Holdings — ACUTA CAPITAL PARTNERS, LLC

Total Portfolio Value:
$140.59M
Total Bought:
$33.42M
Total Sold:
$49.85M
Net Transaction:
-$16.43M
Securities
▲▼
SharesValue
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Praxis Precision Medicines, Inc.(PRAX)83,03684,901+1,865$24.47M$27.35M19.46%+$2.88M
Terns Pharmaceuticals Inc637,095495,772-141,323$25.74M$26.14M18.59%+$398.5K
Whitehawk Therapeutics, Inc.(WHWK)3,410,4023,410,4020$8.25M$11.77M8.37%+$3.51M
Tango Therapeutics, Inc.(TNGX)282,732441,831+159,099$2.51M$9.24M6.57%+$6.74M
Bright Minds Biosciences Inc.(DRUG)84,477111,996+27,519$6.59M$8.17M5.81%+$1.58M
Sutro Biopharma, Inc.(STRO)67,451269,425+201,974$780.4K$6.71M4.77%+$5.93M
Erasca, Inc.(ERAS)0354,575+354,575$0$5.74M4.08%+$5.74M
Surrozen, Inc.(SRZN)178,415172,847-5,568$4.03M$5.04M3.58%+$1.00M
Ocular Therapeutix, Inc.(OCUL)1,052,995592,108-460,887$12.78M$5.02M3.57%-$7.77M
Compass Therapeutics, Inc.(CMPX)1,093,300849,076-244,224$5.87M$4.49M3.19%-$1.38M
Minerva Neurosciences, Inc.(NERV)709,500709,5000$2.85M$4.27M3.04%+$1.42M
MoonLake ImmunotherapeuticsCLASS ORD A(MLTX)59,280191,760+132,480$781.3K$3.57M2.54%+$2.79M
argenx SEADR(ARGX)4,8514,690-161$4.08M$3.42M2.44%-$654.6K
Oculis Holding AG(OCS)101,77798,339-3,438$2.03M$2.61M1.86%+$582.3K
Revolution Medicines, Inc.(RVMD)8,41126,069+17,658$669.9K$2.54M1.80%+$1.87M
4d Molecular Therapeutics Inc0242,255+242,255$0$2.26M1.60%+$2.26M
Amylyx Pharmaceuticals, Inc.(AMLX)333,258151,067-182,191$4.03M$2.10M1.49%-$1.93M
Taysha Gene Therapies, Inc.(TSHA)454,827439,464-15,363$2.50M$1.96M1.40%-$537.1K
IDEAYA Biosciences, Inc.(IDYA)048,234+48,234$0$1.61M1.14%+$1.61M
Design Therapeutics, Inc.(DSGN)150,906145,900-5,006$1.42M$1.55M1.10%+$136.9K
United Therapeutics Corporation(UTHR)2,2962,224-72$1.12M$1.32M0.94%+$200.1K
Entrada Therapeutics, Inc.(TRDA)089,358+89,358$0$1.13M0.80%+$1.13M
Avalo Therapeutics, Inc.(AVTX)060,808+60,808$0$907.9K0.65%+$907.9K
LB Pharmaceuticals Inc(LBRX)30,00028,919-1,081$667.8K$713.1K0.51%+$45.3K
Maze Therapeutics, Inc.(MAZE)20,00019,335-665$828.6K$577.1K0.41%-$251.4K
Unicycive Therapeutics, Inc.(UNCY)59,98557,959-2,026$346.1K$381.4K0.27%+$35.3K
Cidara Therapeutics Inc89,1450-89,145$19.69M$0—-$19.69M
Dianthus Therapeutics, Inc.(DNTH)16,7080-16,708$688.5K$0—-$688.5K
Inhibrx Biosciences, Inc.(INBX)16,3770-16,377$1.29M$0—-$1.29M
Insmed Incorporated(INSM)25,8780-25,878$4.50M$0—-$4.50M
Jazz Pharmaceuticals plcSHS USD(JAZZ)29,0080-29,008$4.93M$0—-$4.93M
Nuvation Bio Inc.W EXP 07 07 2027(NUVB)90,8320-90,832$30.0K$0—-$30.0K
Pasithea Therapeutics Corp.(KTTA)450,0000-450,000$580.5K$0—-$580.5K
Verastem, Inc.(VSTM)143,4460-143,446$1.11M$0—-$1.11M
Zymeworks Inc.(ZYME)80,1430-80,143$2.11M$0—-$2.11M
Page 1 of 1
ACUTA CAPITAL PARTNERS, LLC — 13F Holdings — Q1 2026 | TickerTrail